​Acetylcholinesterase (AChE) is an enzyme that has been identified in Alzheimer’s disease (AD). It is thought to accelerate Aβ aggregation by a rapid increase in hydrolysis of acetylcholine leading to a reduction in cholinergic receptor stimulation and memory loss. Design of small molecule AChE inhibitors has been successful but with limited clinical benefits due to extensive side effects. In this study, we followed a fragment-based drug discovery (FBDD) screening approach to provide insight into designing small molecule inhibitors directly targeting AChE.

Do you have a question or comment for the presenter? Let us know.

To cite this poster: Muzzareli, K., Abdel-Haq, R., Huxkley, A. et al. Fragment-based drug discovery (FBDD) approach for acetylcholinesterase. Poster presented at: 19^th Annual Drug Discovery Chemistry Conference; April 1-4, 2024. San Diego, CA.